Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
Journal
Journal of hepato-biliary-pancreatic sciences
Journal Volume
29
Journal Issue
6
Pages
670
Date Issued
2022-06
Author(s)
Chiu, Tai-Jan
Chiu, Sz-Chi
Hsueh, Shun-Wen
Chiang, Nai-Jung
Li, Chung-Pin
Bai, Li-Yuan
Cheng, Fu-Ming
Chuang, Shih-Chang
Shan, Yan-Shen
Chan, De-Chuan
Chen, Li-Tzong
Yen, Chia-Jui
Peng, Cheng-Ming
Su, Yung-Yeh
Chen, Yen-Yang
Chen, Jen-Shi
Chou, Wen-Chi
Abstract
Recent studies have suggested the suboptimal efficacy of liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients previously treated with conventional irinotecan. This study investigated the effect of conventional irinotecan treatment in mPDAC patients receiving nal-IRI+5-FU/LV by analyzing a population-based dataset.
Subjects
conventional irinotecan; liposomal irinotecan; outcome; pancreatic cancer; propensity score matching
SDGs
Publisher
WILEY
Type
journal article